Pharmacotherapy of atrial fibrillation

Bibliography

• FEINBERG WM, BLACKSHEAR JL, LAUPACIS A, KRONMAL R, HART RG: Prevalence, age distribution and gender in patients with atrial fibrillation: analysis and implica-tions. Arch. Intern. Med. (1995) 155:469–473.
   PubMed Web of Science ®Google Scholar
• BENJAMIN EJ, LEVY D, VAZIRI SM, D'AGOSTINO RB, BELANGER AJ, WOLF PA: Independent risk factors for atrial fibrillation in a population-based cohort. JAMA (1994) 271:840–844.
   PubMed Web of Science ®Google Scholar
• WOLF PA, BENJAMIN EJ, BELANGER AJ, KANNEL WB, LEVY D, D'AGOSTINO RB: Secular trends in the prevalence of atrial fibrillation: the Framingham study. Am. Heart J. (1996) 131:790–795.
   PubMed Web of Science ®Google Scholar
• BIALY D, LEHMAN MH, SCHUMACHER DN, STEINMAN RT, MEISSNER MD: Hospitalization for arrhythmias in the United States: importance of atrial fibrillation (abstract). J. Am. Coll. Cardiol. (1992) 19:41A.
   Google Scholar
• GAJEWSKI J, SINGER RB: Mortality in an insured popula-tion with atrial fibrillation. JAMA (1981) 245:1540–1544.
   PubMed Web of Science ®Google Scholar
• BENJAMIN EJ, WOLF PA, D'AGOSTINO RB, SILBERHATZ H, KANNEL WB, LEVY D: Impact of atrial fibrillation on the risk of death. The Framingham heart study. Circulation (1998) 98:946–952.
   PubMed Web of Science ®Google Scholar
• WOLF PA, ABBOTT RD, KANNEL WB: Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke (1991) 22:983–988.
   PubMed Web of Science ®Google Scholar
• LOK NS, LAU CP: Presentation and management of patients admitted with atrial fibrillation: a review of 291 cases in a regional hospital. Int. J. Cardiol. (1995) 48:271–278.
   PubMedGoogle Scholar
• PRYSTOWSKY EN, BENSON DW, FUSTER V etal: Manage-ment of patients with atrial fibrillation. A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation (1996) 93:1262–1277.
   Google Scholar
• KOPECKY SL, GERSH BJ, MCGOON MD et al.: The naturalhistory of lone atrial fibrillation: a population-based study over three decades. New Engl. J. Med. (1987) 317:669–674.
   PubMed Web of Science ®Google Scholar
• •Low incidence of thromboembolism in 'lone' AF demonstrated.
   Google Scholar
• WOLF PA, DAWBER TR, THOMAS HE, JR., KANNEL WB: Epidemiologic assessment of chronic atrial Exp. Opin. Pharmacother. (1999) 1(1) fibrillation and risk of stroke: the Framingham study. Neurology (1978) 28:973–977.
   Google Scholar
• HORSTKOTTE D: Arrhythmias in the natural history ofmitral stenosis. Acta Cardiologica (1992) 42:105–113.
   Google Scholar
• ATRIAL FIBRILLATION INVERSTIGATORS: Risk factorsfor stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. (1994) 154:1449–1457.
   Google Scholar
• •Meta-analysis of risk factors for thromboembolism from large randomised anticoagulation trials.
   Google Scholar
• THE STROKE PREVENTION IN ATRIAL FIBRILLATION INVESTIGATORS: Predictors of thromboembolism in atrial fibrillation, II: echocardiographic features of patients at risk. Ann. Intern. Med. (1992) 116:6–12.
   PubMed Web of Science ®Google Scholar
• BLACKSHEAR JL, PEARCE LA, ASINGER RW et al.: Mitralregurgitation associated with reduced thromboem-bolic events in high-risk patients with nonrheumatic atrial fibrillation. Am. J. Cardiol. (1993) 72:840–843.
   PubMedGoogle Scholar
• PETERSEN P, GODTFREDSEN J, BOYESEN G, ANDERSEN ED, ANDERSEN B: Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboem-bolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet (1989) i:175–179.
   Google Scholar
• ••The first of the large, randomised trials demonstratingbenefit of anticoagulation in AF.
   Google Scholar
• THE BOSTON AREA ANTICOAGULATION TRIAL FOR ATRIAL FIBRILLATION INVESTIGATORS: The effect of low-dose warfarin on the risk of stroke in the patients with nonrheumatic atrial fibrillation. New Engl. J. Med. (1990) 323:1505–1511.
   PubMed Web of Science ®Google Scholar
• ••A large trial of anticoagulation demonstrating decrease inthromboembolism.
   Google Scholar
• THE STROKE PREVENTION IN ATRIAL FIBRILLATION INVESTIGATORS: Stroke prevention in atrial fibrilla-tion study: final results. Circulation (1991) 84:527–539.
   PubMedGoogle Scholar
• •A large trial of anticoagulation demonstrating decrease in thromboembolism.
   Google Scholar
• EZEKOWITZ MD, BRIDGERS SL, JAMES KE et al.: Warfarin in the prevention of stroke associated with nonrheu-matic atrial fibrillation. New Engl. J. Med. (1992) 327:1406–1412.
   PubMed Web of Science ®Google Scholar
• •A large trial of anticoagulation demonstrating decrease in thromboembolism.
   Google Scholar
• THE STROKE PREVENTION IN ATRIAL FIBRILLATION INVESTIGATORS: Warfarin versus aspirin for preven-tion of thromboembolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study. Lancet (1994) 343:687–691.
   PubMed Web of Science ®Google Scholar
• THE STROKE PREVENTION IN ATRIAL FIBRILLATION INVESTIGATORS: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III study. Lancet (1996) 348:633–638.
   PubMed Web of Science ®Google Scholar
• •Demonstrates superiority of usual warfarin regimen over ASA plus low dose warfarin in higher-risk patients.
   Google Scholar
• THE EAFT STUDY GROUP: Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet (1993) 342:1255–1262.
   PubMedGoogle Scholar
• •Demonstrates superiority of warfarin over ASA in patients with prior CVA.
   Google Scholar
• CONNOLLY SJ, LAUPACIS A, GENT M, ROBERTS RS, CAIRNS JA, JOYNER C: Canadian atrial fibrillation anticoagulation (CAFA) study. J. Am. Coll. Cardiol. (1991) 18:349–355.
   PubMed Web of Science ®Google Scholar
• HYLEK EM, SKATES SJ, SHEEHAN MA, SINGER DE: An analysis of the lowest effective intensity of prophy-lactic anticoagulation for patients with nonrheumatic atrial fibrillation. New Engl. J. Med. (1996) 335:540–546.
   PubMed Web of Science ®Google Scholar
• LAUPACIS A, ALBERS G, DALEN G, DUNN M, FEINBERG W, JACOBSON A: Antithrombotic therapy in atrial fibrillation. Chest (1995) 108:352S–359S.
   Google Scholar
• BJERKELUND CJ, ORNING OM: The efficacy of antico-agulant therapy in preventing emboembolism related to D.C. electrical conversion of atrial fibrillation. Am. J. Cardiol. (1969) 23:208–216.
   Google Scholar
• •Of historical interest; anticoagulation decreases stroke after DC cardioversion.
   Google Scholar
• WEIGNER MJ, CAULFIELD TA, DANIAS PG, SILVERMANN DI, MANNING WJ: Risk of clinical thromboembolism associated with cardioversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann. Intern. Med. (1997) 126:615–620.
   PubMed Web of Science ®Google Scholar
• •Risk of thromboembolism after cardioversion is low in short-lasting AF episodes even in absence of prior anticoagulation.
   Google Scholar
• MANNING WJ, SILVERMAN DI, KEIGHLEY CS, OETTGEN P, DOUGLAS PS: Transesophageal echocardiography facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J. Am. Coll. Cardiol (1995) 25 :1354–1361.
   PubMed Web of Science ®Google Scholar
• KLEIN AL, GRIMM RA, BLACK IW et al.: Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study. A randomized, controlled trial. Assessment of cardioversion using transesophageal echocardiography. Ann. Intern. Med. (1997) 126:200–209
   Google Scholar
• HARENBERG J, HUHLE G, PIAZOLO L, GIESE C, HEENE DL: Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular weight heparin. Semin. Thromb. Hem ost. (1997) 23:167–172.
   PubMedGoogle Scholar
• HARENBERG J, WEUSTER B, PFITZER M et al.: Prophy-laxis of embolic events in patients with atrial fibrilla-tion using low molecular weight heparin. Seminars Thrombosis Hemostasis (1993) 19 Suppl. 1:116–121.
   Google Scholar
• THE DIGITALIS IN ACUTE ATRIAL FIBRILLATION TRIALGROUP: Intravenous digoxin in acute atrial fibrilla-tion. Eur. Heart J. (1997) 18:649–654.
   PubMedGoogle Scholar
• BIANCONI L, MENNUNI M: Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation. Am. J. Cardiol (1998) 82:584–588.
   PubMedGoogle Scholar
• FALK RH, KNOWLTON AA, BERNARD SA, GOTLIEB NE, BATTINELLI NJ: Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blind trial. Ann. Intern. Med. (1987) 106:503–506.
   PubMed Web of Science ®Google Scholar
• •Lack of digoxin's efficacy for sinus rhythm restoration demonstrated.
   Google Scholar
• BEASLEY R, SMITH DA, MCHAFFIE DJ: Exercise heart rates in patients with different serum digoxin concen-trations in patients with atrial fibrillation. Br. Med. J. (1985) 290:9–11.
   PubMed Web of Science ®Google Scholar
• •Digoxin may provide suboptimal rate control with exercise even with optimal dosing.
   Google Scholar
• RAWLES JM, METCALFE MJ, JENNINGS K: Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br. Heart J. (1990) 63:225–227.
   PubMedGoogle Scholar
• DIBIANCO R, MORGANROTH J, FREITAG JA et al.: Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am. Heart J. (1984) 108:1121–1127.
   PubMed Web of Science ®Google Scholar
• WAXMAN HL, MYERBURG RJ, APPEL R, SUNG RJ: Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter. Ann. Intern. Med. (1981) 94:1–6.
   PubMed Web of Science ®Google Scholar
• UEHARA A, HUME JR: Interactions of organic calcium channel antagonists with calcium channels in single frog atrial cells. J. Gen. Physiol. (1985) 85:621–647.
   PubMedGoogle Scholar
• SALERNO DM, DIAS VC, KLEIGER RE et al: Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. Am. J. Cardiol. (1989) 63:1046–1051.
   PubMed Web of Science ®Google Scholar
• GOETTE A, HONEYCUTT C, LANGBERG JJ: Electricalremodeling in atrial fibrillation. Time course and mechanisms. Circulation (1996) 94:2968–2974.
   PubMed Web of Science ®Google Scholar
• TIELEMAN RG, DELANGEN D, VAN GELDER IC et al: Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation (1997) 95:1945–1953.
   PubMed Web of Science ®Google Scholar
• DAOUD EG, KNIGHT BP, WEISS R et al.: Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation (1997) 96:1542–1550.
   PubMedGoogle Scholar
• TIELEMAN RG, VAN GELDER IC, CRIJNS HJGM et al.: Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J. Am. Coll. Cardiol. (1998) 31:167–173.
   PubMed Web of Science ®Google Scholar
• DESIMONE A, STABILE G, VITALE DF: Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J. Am. Coll Cardiol (1999) 34:810–814.
   PubMedGoogle Scholar
• ANDERSON S, BLANSKI L, BYRD RC et al.: Comparison of the efficacy and safety of esmolol, a short acting beta blocker, with placebo in the treatment of supraven-tricular arrhythmias. Am. Heart J. (1986) 111:42–48.
   PubMedGoogle Scholar
• KOWEY PR, TAYLOR JE, RIALS SJ, MARINCHAK RA: Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am. J. Cardiol. (1992) 69:963–965.
   PubMed Web of Science ®Google Scholar
• •Perioperative 0-blockade decreases postoperative AF.
   Google Scholar
• ANDREWS TC, REIMOLD SC, BERLIN JA, ANTMAN EM: Prevention of supraventricular arrhythmias after coronary artery bypass surgery: a meta-analysis of randomized control trials. Circulation (1991) 84 (Suppl.
   Google Scholar
• •Perioperative 0-blockade decreases postoperative AF.
   Google Scholar
• SCARDI S, HUMMAR F, PANDULLO C, POLETI A: Oral clonidine for heart rate control in chronic atrial fibril-lation. Lancet (1993) 341:1211–1212.
   PubMedGoogle Scholar
• HALINEN MO, HUTTUNEN M, PAAKKINEN S, TARSSANEN L: Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the sotalol-digoxin-quinidine trial). Am. J. Cardiol (1995) 76:495–498.
   PubMed Web of Science ®Google Scholar
• HOHNLOSER SH, VAN DE LOO A, BAEDEKER F: Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. I Am. Coll. Cardiol. (1995) 26:852–858.
   PubMed Web of Science ®Google Scholar
• MCALISTER HF, LUKE RA, WHITLOCK RM, SMITH WM: Intravenous amiodarone bolus versus oral quinidine for atrial flutter and fibrillation after cardiac operations. J. Thorac. Cardiovasc. Surg. (1990) 99:911–918.
   PubMedGoogle Scholar
• COPLEN SE, ANTMAN EM, BERLIN JA, HEWITT P, CHALMERS TC: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized controlled trials. Circulation (1990) 82:1106–1116.
   Google Scholar
• •Treatment of AF with quinidine increases mortality.
   Google Scholar
• LEE HS, CHEN SA, TAI CT et al: Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. J. Intern. Med. (1996) 239:253–260.
   PubMedGoogle Scholar
• JUUL-MOLLER S, EDVARDSSON AN, REHNQUIST-AHLBERG N: Sotalol versus quinidine for the mainte-nance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation (1990) 82:1932–1939.
   PubMed Web of Science ®Google Scholar
• NACCARELLI GV, DORIAN P, HOHNLOSER SH, COUMEL P: Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibril-lation/flutter. Am. J. Cardiol. (1996) 77:53A–59A.
   Google Scholar
• KOCHIADAKIS GE, IGOUMENIDIS NE, SOLOMOU MC et al.: Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion. Cardiovasc. Drugs Ther. (1998) 12:75–81.
   PubMedGoogle Scholar
• MADRID AH, MORO C, MARIN-HUERTA E, MESTRE JL, NOVO L, COSTA A: Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur. Heart J. (1993) 14:1127–1131.
   PubMed Web of Science ®Google Scholar
• VOLGMAN AS, CARBERRY PA, STAMBLER B et al: Conver-sion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J. Am. Coll. Cardiol. (1998) 31:1414–1419.
   PubMed Web of Science ®Google Scholar
• GAVAGHAN TP, KEOGH AM, KELLY RP, CAMPBELL TJ, THORBURN C, MORGAN JJ: Flecainide compared with a combination of digoxin and disopyramide for acute atrial arrhythmias after cardiopulmonary bypass. Br. Heart J. (1988) 60:497–501.
   PubMedGoogle Scholar
• CAMPBELL T, GAVAGHAN T, MORGAN J: Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with digoxin and disopyramide in a randomized trial. Br. Heart J. (1985) 54:86–90.
   Google Scholar
• KARLSON BW, TORSTENSSON I, ABJORN C, JANSSON SO, PETERSON LE: Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrilla-tion. A placebo-controlled, one-year follow-up study. Eur. Heart J. (1988) 9:284–290.
   Google Scholar
• RASMUSSEN K, ANDERSEN A, ABRAHAMSEN AM, OVERSKEID K, BATHEN J: Flecainide versus disopyra-mide in maintaining sinus rhythm following conver-sion of chronic atrial fibrillation (abstract). Eur. Heart J. (1988) 9:1–52.
   Google Scholar
• CRIJNS HJGM, GOSSELINK ATM, LIE KI: Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. Cardio-vasc. Drugs Ther. (1996) 10:145–152.
   PubMedGoogle Scholar
• CAPUCCI A, BORIANI G, BOTTO GL et al.: Conversion of recent onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am. J. Cardiol. (1994) 74:503–505.
   PubMedGoogle Scholar
• BORIANI G, BIFFI M, CAPPUCI A et al.: Oral propafenoneto convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A random-ized, controlled trial. Ann. Intern. Med. (1997) 126:621–625.
   PubMed Web of Science ®Google Scholar
• BELLANDI F, CANTINI F, TIZIANA P, PALCHETTI R, BAMOSHMOOSH M, DABIZZI RP: Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: a placebo-controlled study. Clin. Cardiol (1995) 18:631–634.
   PubMedGoogle Scholar
• CAPUCCI A, LENZI T, BORIANI G et al.: Efficacy of propafenone to convert atrial fibrillation into sinus rhythm: a controlled study comparing acute intrave-nous vs. oral loading (abstract). Circulation (1993) 88:1–445.
   Google Scholar
• SUTTORP MJ, KINGMA JH, JESSURUN ER, LIE-A-HUEN L, VANHEMEL NM, LIE KI: The value of class Ic antiar-rhythmic drugs for acute conversion of acute atrial fibrillation or flutter to sinus rhythm. J. Am. Coll. Cardiol (1990) 16:1722–1727.
   PubMed Web of Science ®Google Scholar
• DI BIASI P, SCROFANI R, PAJE A, CAPPIELLO E, MANGINI A, SANTOLI C: Intravenous amiodarone vs. propafe-none for atrial fibrillation and flutter after cardiac operation. Eur.J. Cardiothor. Surg. (1995) 9:587–591.
   Google Scholar
• LARBUISSON R, VENNEMAN I, STIELS B: The efficacy and safety of intravenous propafenone versus intrave-nous amiodarone in conversion of atrial fibrillation or flutter after cardiac surgery. J. Cardiothor. Vasc. Anesth. (1996) 10:229–234.
   PubMedGoogle Scholar
• KOCHIADAKIS GE, IGOUMENIDIS NE, PARTHENAKIS Fl,CHLOUVERAKIS GI, VARDAS PE: Amiodarone versus propafenone for conversion of chronic atrial fibrilla-tion: results of a randomized, controlled study. J. Am. Coll. Cardiol. (1999) 33:966–971.
   PubMed Web of Science ®Google Scholar
• BIANCONI L, MENNUNI M, LUKIC V, CASTRO A, CHIEFFI M, SANTINI M: Effects of oral propafenone administra-tion before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J. Am. Coll. Cardiol. (1996) 28:700–706.
   PubMedGoogle Scholar
• REIMOLD SC, CANTILLON CO, FRIEDMAN PL, ANTMANEM: Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am. J. Cardiol. (1993) 71:558–563.
   PubMed Web of Science ®Google Scholar
• UK PROPAFNONE PSVT STUDY GROUP: A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circula-tion (1995) 92:2550–2557.
   PubMedGoogle Scholar
• STROOBANDT R, STIELS B, HOEBRECHTS R: Propafe-none for conversion and prophylaxis of atrial fibrilla-tion. Am. J. Cardiol (1997) 79:418–423.
   PubMed Web of Science ®Google Scholar
• CHIMIENTI M, CULLEN MT, CASADEI G: Safety of long-term flecainide and propafenone in the manage-ment of patients with symptomatic paroxysmal atrial fibrillation: report from the flecainide and propafe-none Italian study investigators. Am. J. Cardiol. (1996) 77:60A–65A.
   Google Scholar
• ALIOT E, DENJOY I: Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic atrial fibrilla-tion/flutter. Am. J. Cardiol. (1996) 77:66A–71A.
   Google Scholar
• BOTTO GL, BONINI W, BROFFONI T et al.: Conversion of recent onset atrial fibrillation with single loading dose of propafenone: is in-hospital admission absolutely necessary? PACE (1996) 19: 1939-1943.
   Google Scholar
• ECHT DS, LIEBSON PR, MITCHELL LB et al.: Mortality and morbidity in patients receiving encainide, flecainide or placebo. The Cardiac Arrhythmia Suppression Trial. New. Engl. J. Med. (1991) 324:781–788.
   PubMed Web of Science ®Google Scholar
• ••Marked increase in mortality in patients treated with class Iagents after MI.
   Google Scholar
• CAPUCCI A, LENZI T, BORIANI G et al.: Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hyperten-sion. Am. J. Cardiol (1992) 70:69–72.
   PubMed Web of Science ®Google Scholar
• SUTTORP MJ, KINGMA JH, LIE-A-HUEN L, MAST EG: Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am. J. Cardiol (1989) 63:693–696.
   PubMed Web of Science ®Google Scholar
• ANDERSON JL, GILBERT EM, ALBERT BL etal.: Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiar-rhythmic therapy: a multicenter, double-blind, crossover study of flecainide and placebo. Circulation (1989) 80:1557–1570.
   Google Scholar
• BELLANDI F, DABIZZI RP, NICCOLI L, CANTINI F, PALCHETTI R: Propafenone and sotalol: long term efficacy and tolerability in prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study. G. Ital. Cardiol. (1996) 26:379–390.
   PubMedGoogle Scholar
• MACNEIL DJ, DAVIES RO, DEITCHMAN D: Clinical safety profile of sotalol in the treatment of arrhythmias. Am. Cardiol. (1993) 72:44A–50A.
   Google Scholar
• JULIAN DG, PRESCOTT RJ, JACKSON FS, SZEKELY P: Controlled trial of sotalol for one year after myocar-dial infarction. Lancet (1982) 1:1142–1147.
   PubMed Web of Science ®Google Scholar
• WALDO AL, CAMM AJ, DERUYTER H et al.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet (1996) 348:7–12.
   PubMed Web of Science ®Google Scholar
• LEE KS: Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na current in guinea pig ventricular cells. J. Pharmacol. Exp. Ther. (1992) 262:99–108.
   PubMedGoogle Scholar
• ELLENBOGEN KA, STAMBLER BS, WOOD MA et al.: Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J. Am. Coll. Cardiol (1996) 28:130–136.
   PubMed Web of Science ®Google Scholar
• STAMBLER BS, WOOD MA, ELLENBOGEN KA, PERRY KT, WAKEFIELD LK, VANDERLUGT JT: Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation (1996) 94: 1613–1621.
   PubMed Web of Science ®Google Scholar
• ORAL H, SOUZA JJ, MICHAUD GF et al.: Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. New Engl. J. Med. (1999) 340:1849–1854.
   PubMed Web of Science ®Google Scholar
• •Ibutilide increases success rate of DC cardioversion.
   Google Scholar
• FALK RH, POLLAK A, SINGH SN, FRIEDRICH T: Intrave-nous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J. Am. Coll. Cardiol. (1997) 29:385–390.
   PubMedGoogle Scholar
• PEDERSEN OD: Dofetilide in the treatment of atrialfibrillation in patients with impaired left ventricular patients: atrial fibrillation in the DIAMOND study. Circulation (1998) 98:1-632. (Absract).
   Google Scholar
• STRASBERG B, ARDITTI A, SCLAROVSKY S, LEWIN RF, BUIMOVICI B, AGMON J: Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response. Int. J. Cardiol (1985) 7:47–58.
   PubMedGoogle Scholar
• HORNER SM: A comparison of cardioversion of atrial fibrillation using oral amiodarone, intravenous amiodarone and DC cardioversion. Acta Cardiol (1992) 47:473–480.
   PubMedGoogle Scholar
• COWAN JC, GARDINER P, REID DS, NEWELL DJ, CAMPBELL RW: A comparison of amiodarone and digoxin in the treatment of atrial fibrillation compli-cating suspected acute myocardial infarction. J. Cardio-vasc. Pharmacol. (1986) 8:252–256.
   PubMedGoogle Scholar
• GALVE E, RIUS T, BALLESTER R et al.: Intravenousamiodarone in treatment of recent-onset atrial fibrilla-tion: results of a randomized, controlled study. J. Am. Coll. Cardiol. (1996) 27:1079–1082.
   PubMed Web of Science ®Google Scholar
• BLEVINS RD, KERIN NZ, BENADERET D et al.:Amiodarone in the management of refractory atrial fibrillation. Arch. Intern. Med. (1987) 147:1401–1404.
   PubMedGoogle Scholar
• VITOLO E, TRONCI M, LAROVERE MT, RUMORO R, MORABITO A: Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol. (1981) 36:431–444.
   PubMed Web of Science ®Google Scholar
• KOCHIADAKIS GE, IGOUMENIDIS NE, MARKETOU ME, SOLOMOU MC, KANOUPAKIS EM, VARDAS PE: Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am. J. Cardiol. (1998) 81:995–998.
   PubMed Web of Science ®Google Scholar
• GOSSELINK ATM, CRIJNS HJGM, VAN GELDER IC, HILLIGE H, WIESFELD ACP, LIE KI: Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or atrial flutter. JAMA (1992) 267:3289–3293.
   PubMedGoogle Scholar
• ROBINSON K, FRENNEAUX MP, STOCKINS B, KARATASAKIS G, POLONIECKI JD, MCKENNA WJ: Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J. Am. Coll. Cardiol. (1990) 15:1279–1285.
   PubMed Web of Science ®Google Scholar
• DAOUD EG, STRICKBERGER SA, MAN KC et al: Preopera-tive amiodarone as prophylaxis against atrial fibrilla-tion after heart surgery. New Engl. J. Med. (1997) 337:1785–1791.
   PubMed Web of Science ®Google Scholar
• •Short-term oral amiodarone decreases incidence of perioperative AF.
   Google Scholar
• DOVAL HC, NUL DR, GRANCELLI HO, PERRONE SV, BORTMAN GR, CURIEL R: Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet (1994) 344:493–498.
   PubMed Web of Science ®Google Scholar
• •Amiodarone is safe in CHF.
   Google Scholar
• SINGH SN, FLETCHER RD, FISHER SG et al.: Amiodarone in patients with congestive heart failure and asympto-matic ventricular arrhythmia. New Engl. J. Med. (1995) 333: 77–82.
   PubMed Web of Science ®Google Scholar
• •Amiodarone safe in CHF.
   Google Scholar
• HOHNLOSER SH, KLINGENHEBEN T, SINGH BN: Amiodarone-associated proarrhythmic affects. Ann. Intern. Med. (1994) 121:529–535.
   PubMed Web of Science ®Google Scholar
• DUSMAN RE, STANTON MS, MILES WM et al.: Clinical features of amiodarone-induced pulmonary toxicity. Circulation (1990) 82:51–59.
   PubMed Web of Science ®Google Scholar
• PRITCHETT E, PAGE R, CONNOLLY S, MARCELLO S, SCHNELL D, WILKINSON W: Azimilide treatment of atrial fibrillation (abstract). Circulation (1998) 98:1–633.
   PubMedGoogle Scholar
• CLEMO HF, WOOD MA, GILLIGAN DM, ELLENBOGEN KA: Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhyth-mias. Am. J. Cardiol. (1998) 81:594–598.
   PubMed Web of Science ®Google Scholar
• BLOSTROM P, EDVARDSSON N, OLSSON SB: Amiodarone in atrial fibrillation. Acta Med. Scand. (1984) 216:517–524.
   PubMedGoogle Scholar
• FRESCO C, PROCLEMER A, PAVAN A et al.: Intravenous propafenone in atrial fibrillation: paroxysmal. A randomized, placebo controlled double-blind multi-center clinical trial. Clin. Cardiol (1996) 19:409–412.
   Google Scholar
• BLACK IW, FATKIN D, SAGAR KB et al.: Exclusion of atrial thrombus by transeophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study. Circulation (1994) 89:2509–2513.
   PubMed Web of Science ®Google Scholar
• FATKIN D, KUCHAR DL, THORBURN CW, FENELEY MP: Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence of 'atrial stunning' as a mechanism of thromboembolic complications. J. Am. Coll. Cardiol. (1994) 23:307–316.
   PubMed Web of Science ®Google Scholar
• THE PLANNING AND STEERING COMMITTEES OF THE AFFIRM STUDY FOR THE NHLBI AFFIRM INVESTIGATORS: Atrial fibrillation follow-up investigation of rhythm management - the AFFIRM study design. Am. J. Cardiol. (1997) 79:1198–1202.
   PubMedGoogle Scholar
• HOHNLOSER SH, KUCK KH: Atrial fibrillation: maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: the PIAF trial. PACE (1997) 20:1989–1992.
   Google Scholar
• VAN GELDER IC, CRIJNS HJ, VAN GILST WH, VERWER R, LIE KI: Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am. J. Cardiol. (1991) 68:41–46.
   PubMed Web of Science ®Google Scholar
• FLAKER GC, BLACKSHEAR JL, MCBRIDE R, KRONMAL RA, HALPERIN JL, HART RG: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J. Am. Coll. Cardiol. (1992) 20:527–532.
   PubMed Web of Science ®Google Scholar
• ANDERSON JL: Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: the United States experience. Am. J. Cardiol. (1992) 70:11A–18A.
   Google Scholar
• CAIRNS JA, CONNOLLY SJ, ROBERTS R, GENT M: Random-ized trial of outcome after myocardial infarction in patients with frequent repetitive ventricular premature depolarizations: CAMIAT. Lancet (1997) 349:675–682.
   PubMed Web of Science ®Google Scholar
• •Amiodarone is safe after MI.
   Google Scholar
• JULIAN DG, CAMM AJ, FRANGIA G et al.: Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocar-dial infarction: EMIAT. Lancet (1997) 349:667–674.
   PubMedGoogle Scholar
• •Amiodarone is safe after MI.
   Google Scholar
• CHUNG MK, SCHWEIKERT RA, WILKOFF BL et al.: Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J. Am. Coll. Cardiol. (1998) 32:169–176.
   PubMed Web of Science ®Google Scholar
• CAMPBELL RWF, SMITH RA, GALLAGHER JJ, PRITCHETT ELC, WALLACE AG: Atrial fibrillation in the pre-excitation syndrome. Am. J. Cardiol. (1977) 40:514–520.
   PubMedGoogle Scholar
• RODRIGUEZ LM, SMEETS JLRM, XIE B et al.: Improve-ment in left ventricular function by ablation of atriov-entricular conduction in selected patients with lone atrial fibrillation. Am. J. Cardiol (1993) 72:1137–1141.
   PubMed Web of Science ®Google Scholar
• REIFFEL JA: Improved rate control in atrial fibrillation. Am. J. Cardiol (1992) 123:1094–1098.
   Google Scholar
• COUMEL P: Neurogenic and humoral influences of the autonomic nervous system in the determination of paroxysmal atrial fibrillation. In: The Atrium in Health and Disease. Atteul P, Coumel P, Janse MJ (Eds.) Futura Publishing Co., Mount Kisco, New York, USA (1989)213–232.
   Google Scholar
• COUMEL P: Cardiac arrhythmias and the autonomic nervous system. J. Cardiovasc. Electrophysiol. (1993) 4:338–355.
   PubMed Web of Science ®Google Scholar
• LEITCH JW, THOMSON D, BAIRD DK. HARRIS PJ: The importance of age as a predictor of atrial fibrillation and flutter after coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. (1990) 100:338–342.
   Google Scholar
• CRES WELL LL, SCHUESSLER RB, ROSENBLOOM M, COX JL: Hazards of postoperative atrial arrhythmia. Ann. Thorac. Surg. (1993) 56:539–549.
   PubMedGoogle Scholar
• BELHASSEN B, PAUZNER D, BLIEDEN L et al.: Intrau-terine and postnatal atrial fibrillation in the Wolff-Parkinson-White syndrome. Circulation (1982) 66:1124–1128.
   PubMedGoogle Scholar
• GREENWOOD RD, ROSENTHAL A, SLOSS LJ, LACORTE M, NADAS AS: Sick sinus syndrome after surgery for congenital heart disease. Circulation (1975) 52:208–213.
   PubMedGoogle Scholar
• BRUGADA R, TAPSCOTT T, CZERNUSZEWICZ GZ et al.: Identification of a genetic locus for familial atrial fibrillation. New Engl. J. Med. (1997) 336:905–911.
   PubMed Web of Science ®Google Scholar